MRI靶向穿刺联合系统穿刺在前列腺癌主动监测确认活检中的效果比较
本研究基于主动监测数据库匹配队列,比较MRI靶向联合系统穿刺(MRI-biopsy)与单纯系统穿刺(SB)在确认活检中的表现。匹配后各257例,MRI-biopsy组升级率45.9%高于SB组17.9%,阴性活检率12.5%低于37.7%,MRI-biopsy与确认活检升级(GG1升至≥GG2)的比值比为3.62。
要点
- MRI靶向联合系统穿刺较单纯系统穿刺显著降低确认活检阴性率
- MRI-biopsy组确认活检升级率显著高于SB组
- MRI-biopsy与GG1升级至≥GG2的比值比为3.62
核心结论
- 在既往确诊前列腺癌并接受主动监测的男性中,确认活检时在系统穿刺基础上加做MRI靶向穿刺,较单纯系统穿刺减少阴性活检并检出更多临床显著前列腺癌。
研究设计与样本
- 回顾性匹配队列研究,患者来自主动监测数据库,2006至2019年单中心,既往经直肠超声引导系统穿刺阳性后接受确认活检。
- 按确认活检技术分为单纯系统穿刺组和MRI-biopsy组(含MRI靶向及系统穿刺),按年龄、PSA、初始活检阳性针数及Gleason分级组匹配,匹配后共514例,每组257例。
主要发现
- 确认活检后MRI-biopsy组升级118/257例(45.9%),SB组46/257例(17.9%),P < 0.001。
- 确认活检阴性率MRI-biopsy组32/257例(12.5%),SB组97/257例(37.7%),P < 0.001。
- 确认MRI-biopsy与从GG1升级至≥GG2的比值比为3.62(95%CI 1.97-6.63;P < 0.001)。
临床怎么用
- 对于既往确诊前列腺癌并进入主动监测的男性,确认活检时采用MRI靶向联合系统穿刺可减少阴性活检并提高临床显著癌检出。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the ability of magnetic resonance imaging (MRI)-targeted biopsy combined with systematic biopsy (MRI-biopsy) to reduce negative biopsies and detect clinically significant prostate cancer compared to systematic biopsy (SB) alone in the confirmatory biopsy setting using matched cohorts. PATIENTS AND METHODS: Patients were identified from an active surveillance database who had a previously positive transrectal ultrasonography-guided SB followed by a confirmatory biopsy at a single institution between 2006 and 2019. Patients were divided into two cohorts based on confirmatory biopsy technique: SB alone or MRI-biopsy (which included MRI-targeted and systematic biopsies). Cohorts were then matched on age, prostate-specific antigen (PSA) level, number of positive cores on initial biopsy and initial biopsy Gleason grade group (GG). Logistic regression was performed to identify associations with confirmatory biopsy upgrading. RESULTS: After matching, 514 patients were identified (257 per cohort). PSA, prostate volume and PSA density prior to initial biopsy, in addition to total number of initial biopsy positive cores and GG, were similar between the matched cohorts. After confirmatory biopsy, 118/257 patients (45.9%) in the MRI-biopsy cohort were upgraded compared to 46/257 patients (17.9%) in the SB cohort (P < 0.001). The rate of negative confirmatory biopsy was 32/257 (12.5%) compared to 97/257 (37.7%) in the MRI-biopsy and SB cohorts, respectively (P < 0.001). Confirmatory MRI-biopsy was associated with greater odds of confirmatory biopsy upgrade from GG 1 to ≥GG 2 compared to SB alone (odds ratio 3.62, 95% confidence interval 1.97-6.63; P < 0.001). CONCLUSION: The addition of MRI-targeted biopsies to SB in the confirmatory biopsy setting among men with previously detected prostate cancer resulted in fewer negative confirmatory biopsies and detection of more clinically significant prostate cancer compared to SB alone.
引用
- Shapiro DD, Gregg JR, Lim AH, et al. Comparing confirmatory biopsy outcomes between MRI-targeted biopsy and standard systematic biopsy among men being enrolled in prostate cancer active surveillance. BJU Int. 2020. PMID: 32357283. doi:10.1111/bju.15100
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。